

# BC PharmaCare Drug Information

The drug below is being considered for coverage under the BC PharmaCare program. PharmaCare is a government-funded drug plan that helps B.C. residents with the cost of eligible prescription drugs and medical supplies. For more information about PharmaCare, visit the [PharmaCare website](#).

PharmaCare reviews each drug for treating a specific illness or medical condition (also called an “indication”). If PharmaCare decides to cover a drug, that coverage applies only to the indication(s) specified. In some cases, PharmaCare covers a drug only for people who have not responded to other drugs that treat the same indication.

More information about the PharmaCare drug review process is provided on the last page of this document.

| Drug information                                                                             |                                                                                                                                         |
|----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Generic name (scientific name)                                                               | <b>nerandomilast</b>                                                                                                                    |
| Brand name                                                                                   | <b>TBC (to be confirmed)</b>                                                                                                            |
| Manufacturer                                                                                 | Boehringer Ingelheim                                                                                                                    |
| Indication                                                                                   | For the treatment of adult patients with idiopathic pulmonary fibrosis (IPF).                                                           |
| Has the drug been reviewed by CDA-AMC, or will CDA-AMC be reviewing it?<br>(See note below.) | Yes<br>For more information about the CDA-AMC Reimbursement Review (CRR) of nerandomilast, <a href="#">Search the CDA-AMC Reports</a> . |
| Public input start date                                                                      | <b>Wednesday, September 30, 2026</b>                                                                                                    |
| Public input closing date                                                                    | <b>Tuesday, October 27, 2026, at 11:59 pm</b>                                                                                           |
| How is the drug taken?                                                                       | Nerandomilast is taken orally (by the mouth).                                                                                           |
| How often is the drug taken?                                                                 | Nerandomilast is taken twice daily with doses administered approximately 12 hours apart.                                                |

| Drug information                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|--------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| General drug and/or drug study information | <p>Nerandomilast is being reviewed by the Ministry of Health for the treatment of idiopathic pulmonary fibrosis in adults.</p> <p>Idiopathic pulmonary fibrosis (IPF) is a serious lung disease that causes progressive scarring of the lungs. The term 'idiopathic' means that the cause is unknown. As scar tissue builds up, the lungs become stiff and less able to move oxygen into the bloodstream. This leads to worsening breathing problems and a gradual decline in lung function over time. Common symptoms of IPF include shortness of breath, a persistent dry cough, fatigue, and increasing difficulty carrying out daily activities. Symptoms typically worsen over time as lung scarring and loss of lung function progress.</p> <p>Nerandomilast is a phosphodiesterase 4B (PDE4B) inhibitor. It works by blocking PDE4B, an enzyme involved in pathways that promote inflammation and scarring in the lungs, which may help slow the progression of pulmonary fibrosis.</p> <p>Studies looked at the following:</p> <ul style="list-style-type: none"> <li>• Absolute change from baseline in forced vital capacity (FVC), measured in millilitres, at Week 52. FVC is the total amount of air a person can forcefully exhale after taking a deep breath.</li> <li>• Absolute change from baseline in forced vital capacity as a percentage of the predicted value<sup>a</sup> at Week 52</li> <li>• Time to the first occurrence of any of the following: acute IPF exacerbation, hospitalization for a respiratory cause, or death (whichever occurs first) over the duration of the study</li> <li>• Time to death over the duration of the study</li> <li>• Absolute changes from baseline in Living with Pulmonary Fibrosis (L-PF) questionnaire symptom scores, including dyspnea (shortness of breath), cough, and fatigue, at Week 52</li> <li>• Bad reactions</li> <li>• Serious bad reactions</li> <li>• Patients leaving the trial due to bad reactions</li> <li>• Bad reactions of special interest: severe drug-induced liver injury, vasculitis (inflammation of the blood vessels), severe, serious, or opportunistic infections, including tuberculosis, and new onset of severe depression or anxiety</li> </ul> |

| Drug information     |      |
|----------------------|------|
| Other considerations | None |

## Note:

CDA-AMC ([Canada's Drug Agency-L'Agence des Médicaments du Canada](#)) is a national organization that reviews drugs on behalf of Canadian public sector plans when drug manufacturers want those plans to provide coverage for the drug. For detailed information about the PharmaCare drug review process, including the role of the CDA-AMC Reimbursement Review (CRR) in that process, visit [How PharmaCare Decides Which Drugs to Cover](#).

| Table of Comparators Used to Treat the Same Indication |             |                                                                  |
|--------------------------------------------------------|-------------|------------------------------------------------------------------|
| Generic Name<br>(Brand Name)<br>of Drug Comparator     | Dosage Form | PharmaCare Status<br>(if and how the drug is<br>already covered) |
| nerandomilast<br>(TBC)                                 | Tablet      | Under Review                                                     |
| <b>Protein Kinase Inhibitor</b>                        |             |                                                                  |
| nintedanib<br>(Ofev, generics)                         | Tablet      | <a href="#">Limited Coverage,<br/>Subject to LCA</a>             |
| <b>Anti-fibrotic</b>                                   |             |                                                                  |
| pirfenidone<br>(Esbriet, generics)                     | Tablet      | <a href="#">Limited Coverage,<br/>Subject to LCA</a>             |

<sup>a</sup> Predicted value refers to the lung function expected for a healthy person with similar characteristics (such as age, sex, and height). Values are expressed as a percentage of this expected level.

### **The Drug Review Process in B.C.**

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent national organization called [Canada's Drug Agency \(CDA-AMC\)](#) provides evidence-based recommendations to public drug plans across Canada through its reimbursement review process.

As part of the CDA-AMC's Clinical Reimbursement Review process, the Canadian Drug Expert Committee (CDEC) makes reimbursement recommendations for non-oncology pharmaceuticals to the participating federal, provincial, and territorial publicly funded drug plans. In developing its recommendations, the CDEC considers:

- whether the drug is safe and effective
- what the drug costs and whether it is a good value to the citizens of B.C.
- ethical considerations related to covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by considering:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the CDA-AMC
- the recommendations and reimbursement conditions of the CDEC
- if a Ministry Initiated review, the advice of an independent expert group called the Drug Benefit Council (DBC)
- BC-specific patient input collected through the Your Voice website
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug

Visit [BC PharmaCare](#) and [Drug reviews](#) for more information.

#### **This document provides information only.**

It does not take the place of advice from a physician or other qualified health care provider.